Latest News - Kala Pharmaceuticals 

Wednesday, July 26, 2017 | Earnings & Financials, Kala Pharmaceuticals 

Kala Pharmaceuticals Announces Close of Initial Public Offering and Exercise of Underwriters’ Option

Kala Pharmaceuticals announced the closing of its initial public offering of 6,900,000 shares of common stock, including the underwriters’ exercise in full of their option to purchase an additio…

Read the full story

Thursday, July 20, 2017 | Earnings & Financials, Kala Pharmaceuticals 

Kala Pharmaceuticals Announces Pricing of Initial Public Offering

Kala Pharmaceuticals announced that is has priced its initial public offering of 6,000,000 shares of its common stock at a public offering price of $15 per share, for aggregate gross proceeds of appro…

Read the full story

Monday, May 01, 2017 | Clinical Trials, Kala Pharmaceuticals 

Kala Pharmaceuticals Announces Positive Results from Confirmatory Phase 3 Trial of KPI-121 1% Following Cataract Surgery

Kala Pharmaceuticals announced positive topline results from its confirmatory phase 3 trial of KPI-121 1% for the treatment of inflammation and pain in patients who have undergone cataract surgery. KP…

Read the full story